Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC
NCT01062503
·
clinicaltrials.gov ↗
COMPLETED
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Prostate Cancer
Bone Metastasis
Interventions
DRUG:
Zoledronic acid
Sponsor
University Health Network, Toronto